Clinical Trial Update: Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

A Phase Ib/II trial is evaluating the combination of Envafolimab (PD-L1 inhibitor) and lenvatinib in patients with solid tumors, including non-small cell lung c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma
• Non-small Cell Lung Cancer
• Renal Cell Carcinoma

Drugs mentioned

• Envafolimab (envafolimab)
• Lenvatinib (lenvatinib)

Snippet

Sponsor: 3D Medicines (Sichuan) Co., Ltd. | Conditions: Solid Tumors, Non-small Cell Lung Cancer | Phase 1, Phase 2 | Status: RECRUITING